Larry Bock
Angel Investor @ Lux Capital
San Diego, United States
Larry Bock is a Series B investor at Lux Capital in San Diego focused on Software and SaaS. Larry Bock is the Co-Founder and Seed Investor of Onyx Pharmaceuticals. He previously worked at Illumina as a Co-Founder. Larry Bock attended the Bowdoin College.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 10%
Last updated:
For AI agents: llms.txt
Industries Larry Bock invests in
Stages Larry Bock invests in
Countries Larry Bock invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Software 2 (20%)
- SaaS 1 (10%)
- Travel 1 (10%)
- Tourism 1 (10%)
- Computer 1 (10%)
Stage
- Series B 3 (30%)
- Seed 2 (20%)
- Series A 2 (20%)
- Series C 1 (10%)
- Funding Round 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Called a Godsend by The New York Times, Aira is on a mission to make the world accessible anywhere, anytime. They provide on-remand, remote visual interpretation services for the blind and low vision community. Download the app, press a button and your phone's camera streams a live video to one our highly screened Visual Interpreters. | $12M / Series B / May 16, 2017 | ||
| Called a Godsend by The New York Times, Aira is on a mission to make the world accessible anywhere, anytime. They provide on-remand, remote visual interpretation services for the blind and low vision community. Download the app, press a button and your phone's camera streams a live video to one our highly screened Visual Interpreters. | $2.6M / Series A / Mar 02, 2016 | ||
| Called a Godsend by The New York Times, Aira is on a mission to make the world accessible anywhere, anytime. They provide on-remand, remote visual interpretation services for the blind and low vision community. Download the app, press a button and your phone's camera streams a live video to one our highly screened Visual Interpreters. | $790K / Seed / Oct 29, 2015 | ||
| ZOZI designs and develops a web-based bookings, payments, and customer management software for tour, activity, and event businesses. | $10M / Series B / Mar 01, 2011 | ||
| ZOZI designs and develops a web-based bookings, payments, and customer management software for tour, activity, and event businesses. | $3M / Series A / Aug 30, 2010 | ||
| ZOZI designs and develops a web-based bookings, payments, and customer management software for tour, activity, and event businesses. | $1.3M / Seed / Aug 01, 2008 | ||
| Nanosys, Inc. researches, develops, and manufactures light-emitting Quantum Dot (QD) technologies for use in a wide range of applications from displays to agriculture. Quantum dots are nanoscale semiconductors that enable displays to reproduce a more lifelike image with a wider range of color and higher brightness. Quantum Dot technologies arecompatible with and offer improved performance for displays of all types including LED-LCDs, OLEDs, and micro-LEDs. As of 2020, consumer electronics brands have shipped more than 20 million devices across over 400 unique products including televisions, monitors, tablets, and automotive interiors based on Nanosys’ proprietary quantum dot technology. | $41.5M / Series C / Nov 09, 2005 | ||
| Nanosys, Inc. researches, develops, and manufactures light-emitting Quantum Dot (QD) technologies for use in a wide range of applications from displays to agriculture. Quantum dots are nanoscale semiconductors that enable displays to reproduce a more lifelike image with a wider range of color and higher brightness. Quantum Dot technologies arecompatible with and offer improved performance for displays of all types including LED-LCDs, OLEDs, and micro-LEDs. As of 2020, consumer electronics brands have shipped more than 20 million devices across over 400 unique products including televisions, monitors, tablets, and automotive interiors based on Nanosys’ proprietary quantum dot technology. | $38M / Series B / Apr 24, 2003 | ||
| Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs. Its internal program portfolio comprises PS433540, a dual-acting angiotensin and endothelin receptor antagonist, which is in phase II clinical development for the treatment of cardiovascular and renaldiseases, including hypertension and diabetic nephropathy; and PS178990, a muscle selective SARM agonists that is in phase I clinical development. The company's products also include PS031291, a preclinical development product for the treatment of multiple myeloma and various inflammatory diseases, including rheumatoid arthritis; and JAK3 inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye. Pharmacopeia has strategic alliances with Bristol-Myers Squibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and Wyeth Pharmaceuticals. The company was founded in 1993. It was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May 2007. Pharmacopeia is based in Cranbury, New Jersey. As of December 23, 2008, Pharmacopeia, Inc. operates as a subsidiary of Ligand Pharmaceuticals Inc. | |||
| See all 10 investments → | |||
Co-Investors
About Lux Capital
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Lux Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Adam Kalish
General Partner
|
|||
Alex Nguyen
Principal
|
|||
Brandon Reeves
Partner
|
|||
Deena Shakir
General Partner
|
|||
Ian Peikon
Venture Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Larry Bock invest in?
Larry Bock invests primarily in Software, SaaS and Travel startups, most often at Series B and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Larry Bock?
Public channels for Larry Bock include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Larry Bock last invest?
The most recent investment recorded for Larry Bock closed in May 2017. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
